Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Leukemia, Myeloid, Acute 3 Myelodysplastic Syndromes 2 Unresectable Colorectal Cancer 1 Solid Tumor 1 Prostatic Neoplasms 1 Pancreatic Neoplasms 1 Ovarian Neoplasms 1 Osteosarcoma 1 Neuroblastoma 1 Lymphoma, Non-Hodgkin 1 Lymphoma, Mantle-Cell 1 Lymphoma, Large B-Cell, Diffuse 1 Lymphoma, Follicular 1 Lymphoma, B-Cell, Marginal Zone 1 Lymphoma, B-Cell 1 Hematologic Neoplasms 1 Brain Neoplasms 1

Interventions

Temozolomide 38 Radiotherapy 22 Radiosurgery 22 Radiation 11 Magnetic Resonance Spectroscopy 11 Irinotecan 11 Cyclophosphamide 11 Etoposide 10 Surgical Procedures, Operative 9 Erlotinib Hydrochloride 9 Carmustine 9 pembrolizumab 8 Filgrastim 8 Carboplatin 8 Bevacizumab 7 Vincristine 6 Sorafenib 6 O(6)-benzylguanine 6 Nivolumab 6 Flucytosine 6 Aminolevulinic Acid 6 temsirolimus 5 sargramostim 5 Vorinostat 5 Trastuzumab 5 Topotecan 5 Lomustine 5 Imatinib Mesylate 5 Granulocyte Colony-Stimulating Factor 5 Everolimus 5

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1 × Brain Neoplasms × magrolimab × Clear all

NCT05169944 2025-07-09

PNOC025

University of California, San Francisco

Phase 1 Completed

Brain Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡